Causes of Subtherapeutic Phenytoin (Epsolin) Blood Levels
The most common causes of subtherapeutic phenytoin levels are inadequate dosing (particularly when using maintenance doses without loading), poor medication adherence, drug interactions that increase metabolism, and administration errors—especially with IV formulations that precipitate when improperly diluted.
Primary Causes
1. Inadequate Dosing Strategy
- Maintenance dosing without loading: Oral phenytoin at standard maintenance doses without a loading dose takes 3-7 days to reach therapeutic levels (≥10 mg/L), and some patients never achieve therapeutic levels without dose increases 1
- Insufficient loading dose: Standard loading doses may be inadequate in certain populations, particularly critically ill patients with increased metabolism 2
- Weight-based dosing errors: Failure to use appropriate mg/kg dosing can result in subtherapeutic levels
2. Patient Non-Adherence
- Poor compliance is a major cause of treatment failure: In one study, 9 of 10 patients receiving ≥300 mg/day with levels <5 mcg/mL were found to be non-compliant when given supervised therapy 3
- Critical pitfall: Subtherapeutic levels can indicate either non-compliance OR need for higher dosing—supervised administration for 5 days can distinguish between these causes 3
3. Administration Errors (IV Formulations)
- Dilution in incompatible solutions: Phenytoin precipitates when diluted in glucose-containing solutions or 0.9% saline infusions, with crystals retained by particle filters, resulting in subtherapeutic levels 4
- Proper IV administration: Must be given directly into large veins, flushed with sterile saline, NOT diluted in IV bags 5, 4
- IM administration: Causes slower absorption and 40-50% drop in peak levels compared to oral dosing due to poor water solubility 5
4. Altered Protein Binding (Appears Subtherapeutic on Total Levels)
- Hypoalbuminemia, renal disease, hepatic disease: Increase the unbound (free) fraction of phenytoin 5
- Critical monitoring error: Total phenytoin levels appear low, but free levels may be therapeutic or even toxic 2
- In critically ill patients: Unbound fraction ranges from 6-18% (vs. 7% in healthy volunteers), requiring monitoring of FREE phenytoin levels 2
- Neonates: Have increased risk due to decreased protein binding 6
5. Increased Metabolism
- Acute brain injury/critical illness: Dramatically increased phenytoin metabolism during ICU phase, requiring dosages of 6 mg/kg/day or higher to achieve therapeutic levels 2
- Metabolism normalizes during convalescence: Dosage requirements decrease over time, necessitating adjustment 2
6. Drug Interactions
- Chemotherapy agents: Cisplatin, vinblastine, and bleomycin can reduce phenytoin absorption to 32% (normal >80%) through cellular-level disruption 7
- Ciprofloxacin: Even topical ciprofloxacin eye drops have been reported to cause subtherapeutic phenytoin levels and breakthrough seizures 8
- CYP2C9 inducers: Phenytoin is metabolized by CYP2C9 and CYP2C19; inducers of these enzymes increase clearance 5, 9
7. Genetic Factors
- CYP2C9 polymorphisms: Genetic variations affect phenytoin metabolism, though typically causing HIGHER levels in slow metabolizers 5, 9
- Slow metabolizers: A small percentage metabolize phenytoin slowly due to limited enzyme availability 5
8. Age-Related Changes
- Elderly patients: Have 20% decreased clearance, but this typically causes HIGHER levels 5
- Neonates and infants: May require different dosing strategies; traditional 15-20 mg/kg loading doses often result in elevated free levels 10
Practical Monitoring Approach
When encountering subtherapeutic levels:
- Verify administration route and technique (especially for IV formulations)
- Check for dilution errors if IV phenytoin was used
- Assess medication adherence through supervised dosing if levels are <5 mcg/mL on ≥300 mg/day 3
- Measure FREE phenytoin levels in patients with hypoalbuminemia, renal/hepatic disease, or critical illness 5, 2
- Review drug interactions, including chemotherapy and antibiotics 7, 8
- Consider increased metabolism in critically ill or brain-injured patients 2
Important caveat: Follow-up monitoring of serum phenytoin levels on an outpatient basis is essential after ED discharge, as levels do not need rechecking before discharge 1.